Mateon Therapeutics (MATN) Stock Price, News & Analysis

Company Overview

Mateon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology therapies that selectively target tumor tissue. The company’s platform leverages tumor-activated peptides designed to bind to the fibrin–fibronectin complexes uniquely present in solid tumors, with the goal of improving the therapeutic index of cytotoxic payloads while limiting off-target effects.

Its lead asset, MH1, is a peptide–drug conjugate in Phase I clinical trials for advanced solid tumors. MH1 is engineered to remain inert in circulation and to be activated by tumor-associated proteases, delivering potent chemotherapeutic agents directly to the tumor microenvironment. Mateon also maintains a preclinical pipeline exploring additional peptide constructs intended to address cancers with high unmet medical need, such as ovarian and colorectal indications.

Headquartered in Redwood City, California, Mateon collaborates with academic research centers and contract development organizations to advance its candidates through IND-enabling studies and early-stage clinical work. The company’s leadership team combines experience in oncology drug development, peptide chemistry and clinical operations, positioning Mateon to progress its targeted therapies toward regulatory milestones and potential strategic partnerships.

Key Stats

• Today's Range: $0.04 to $0.04
• 50-Day Range: $0.03 to $0.05
• 52-Week Range: $0.13 to $0.38
• Volume: 464,920 shs
• Average Volume: 338,444 shs
• Market Capitalization: $3.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MATN Stock Analysis - Frequently Asked Questions

How have MATN shares performed this year?

Mateon Therapeutics' stock was trading at $0.0784 at the beginning of the year. Since then, MATN stock has decreased by 51.9% and is now trading at $0.0377.

How were Mateon Therapeutics' earnings last quarter?

Mateon Therapeutics, Inc. (OTCMKTS:MATN) announced its quarterly earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02).

How do I buy shares of Mateon Therapeutics?

Shares of MATN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mateon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mateon Therapeutics investors own include Amarin (AMRN), Cyclacel Pharmaceuticals (CYCC), Catalyst Pharmaceuticals (CPRX), Oramed Pharmaceuticals (ORMP), Exelixis (EXEL), BioLineRx (BLRX).

Company Calendar

• Last Earnings: 5/15/2019
• Today: 5/06/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:MATN
• Previous Symbol: NASDAQ:MATN
• CIK: 908259
• Web: www.mateon.com
• Phone: 650-635-7000
• Fax: N/A
• Employees: 13
• Year Founded: 1996

Profitability

• EPS (Trailing Twelve Months): ($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.64 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -64.66%
• Return on Assets: -42.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.17
• Quick Ratio: 0.17

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.20 per share
• Price / Book: 0.19

Miscellaneous

• Outstanding Shares: 90,240,000
• Free Float: N/A
• Market Cap: $3.40 million
• Optionable: Not Optionable
• Beta: 1.33